As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
19 Analysts have issued a Disc Medicine forecast:
19 Analysts have issued a Disc Medicine forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -138 -138 |
42%
42%
|
EBIT (Operating Income) EBIT | -138 -138 |
42%
42%
|
Net Profit | -116 -116 |
45%
45%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.
Head office | United States |
CEO | John Quisel |
Employees | 84 |
Founded | 2017 |
Website | www.discmedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.